Amgen Inc. ($AMGN) reported its fourth-quarter earnings for 2024, revealing a revenue of $9.09 billion, which is a 10.86% increase year-over-year and surpasses analyst expectations by $208 million. The adjusted earnings per share (EPS) stood at $5.31, reflecting a 12.74% year-over-year growth and beating estimates by $0.23. The company highlighted strong product sales growth of 11%, driven by significant gains in key drugs such as Repatha, BLINCYTO, and TEZSPIRE. Additionally, Amgen provided guidance for 2025, projecting total revenues between $34.3 billion and $35.7 billion, with non-GAAP EPS expected to range from $20 to $21.20, indicating a robust growth outlook across its therapeutic areas. Boston Scientific ($BSX) also announced its fourth-quarter results, reporting net sales of $4.561 billion, a 22.4% increase compared to the previous year, and adjusted EPS of $0.70, beating estimates of $0.66. The company anticipates full-year adjusted EPS for 2025 to be between $2.80 and $2.87. CDW Corporation ($CDW) reported fourth-quarter net sales of $5.186 billion, exceeding analyst estimates of $4.954 billion, with an adjusted EPS of $2.48, surpassing expectations of $2.32. Fiserv ($FI) posted adjusted EPS of $2.51 on revenues of $5.25 billion, both figures beating analyst estimates, while Cencora ($COR) reported adjusted EPS of $3.73, above the expected $3.50, with sales of $81.49 billion, exceeding estimates of $78.38 billion.